news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

Health is the most important thing for everyone; a healthy body can guarantee a high-quality life. Among various health problems, migraine is a common neurological disease, and its long-term recurrence seriously affects the quality of life of patients. According to statistics, there are more than 100 million potential migraine patients in China, and the number of patients shows a long-term growth trend. However, the diagnosis and treatment capabilities of migraine in China are still insufficient, with the correct diagnosis rate of doctors being only 13.8%, and there are widespread problems such as insufficient preventive treatment and excessive use of analgesics. With the accelerated pace of social life and the increase in work pressure, migraine management has increasingly become a hot topic in public health.

Migraine Alliance launched: a three-party alliance to build a new healthy ecosystem

On August 20, JD Health, together with Zambon Pharmaceuticals and other companies, jointly held the "Bye Bye Migraine" industry conference and officially launched the Migraine Alliance. The alliance has successfully built a tripartite cooperation and exchange platform by uniting enterprises, experts and patients, and is committed to creating the leading migraine treatment program in China and jointly building a new ecosystem for migraine patient management services. At the same time, JD Health also released an "Migraine" industry insight report. Based on a large amount of data accumulated by the JD Health platform, the report systematically outlines the incidence trend of migraine in China, and deeply analyzes the population portrait of migraine patients, providing the industry with in-depth insights into migraine prevalence, medication trends and other aspects, and further provides scientific basis and decision-making support for optimizing patient management and improving treatment effects.

Mr. Zhu Zhiyun, General Manager of Zambon Group China, attended the alliance launch ceremony with doctors, experts and relevant persons in charge of JD Health, and took a group photo. Mr. Zhu Zhiyun, General Manager of Zambon Group China, elaborated on Zambon's more than 30 years of deep cultivation in the field of pain management. He pointed out that China still has deficiencies in the diagnosis and treatment of migraines, and patients lack the correct awareness of medication. With the sharp increase in demand for online drug purchases, patients' health management needs are becoming increasingly prominent. Faced with this situation, Zambon will actively integrate hospitals, pharmacies and e-commerce channels, comprehensively promote patient education, and help more patients master scientific treatment methods. Zambon will carry out in-depth cooperation with the JD Health platform to achieve full coverage from diagnosis, treatment to drug purchase through an innovative full-link doctor-patient marketing model.

Industry event: Discussing the future of pain management

At the founding ceremony of the alliance, a relevant person in charge of JD Health said that JD Health looks forward to jointly promoting the vigorous development of the migraine industry under the guidance of a professional team of doctors and with the help of outstanding companies. JD Health will provide more support to doctors, patients and partners in four areas: disease development research, improvement of diagnosis and treatment levels, patient services and preferential rights for partners.

Free Clinic+live streaming:ExpertisePopular Science,Reaching patients accurately

The event site specially set up booths for major brands. The Zambon booth focused on the field of pain diseases, bringing patients interesting disease science content, and also exhibited Zambon's original research products and disease treatments. In addition, a migraine free clinic area was set up at the booth, where experts patiently listened to the symptoms of each patient, answered the patient's various questions in detail, and provided patients with targeted treatment suggestions and preventive measures.

The event also launched a special live broadcast called "Goodbye Migraine". The head of JD Health personally visited the live broadcast room and gathered with pharmaceutical executives, industry experts and self-media communication experts to discuss and share migraine treatment options.

Yu Xiaoxiao, an expert from the Zambon Medical Department, gave patients a detailed disease science education, and explained in depth the pathogenesis, prevention methods and treatment options of migraine, providing patients with scientific and practical health advice. According to the patient's disease symptoms and treatment needs, Yu Xiaoxiao introduced the important role of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of migraine. Non-steroidal anti-inflammatory drugs (NSAIDs) are first-line drugs for the treatment of mild to moderate migraine attacks and severe migraine attacks that have been effectively treated. By inhibiting the synthesis of prostaglandins, they can effectively reduce the inflammatory response and pain symptoms of migraine. Compared with other types of analgesics, non-steroidal anti-inflammatory drugs have become one of the widely recommended treatment options because of their rapid onset and fewer side effects.

ZambonDeep cultivationMore than 30 years in the pain field, protecting patients' health

As a well-known original research pharmaceutical company in Europe, Zambon has accumulated profound experience in the field of pain relief for more than 30 years. The company's developed Ibuprofen Arginine Granules has become a reliable choice for patients to deal with pain due to its rapid effect in 15 minutes. Participation in the "Bye Bye Migraine" event once again demonstrated Zambon's firm determination to commit to pain management, and will continue to promote the development of the cause of national health with practical actions. Zambon hopes to work with more industry partners to promote new breakthroughs in pain management, continuously improve patients' lives, and benefit the health of the whole people.